分子生物学
IVD分子诊断
细胞培养与分析
蛋白研究
细胞因子
重组蛋白
抗体
高通量测序建库
病原检测UCF系列
生物医药
工具酶
抑制剂激活剂与常用试剂
仪器
耗材

The p. Arg1800His Mutation of Factor VIII Results in Moderate Hemophilia A Due to Defective Processing and Stability of Functional Protein

Han Wang, Jiaqi Tian, Ming Zhang, Liyuan Zhang, Chunxia Liu, Lu Niu, Wenjuan Jia

Journal:CELL BIOLOGY INTERNATIONAL

IF:3.5

DOI:10.1002/cbin.70164

PMID:

Published:2026-05-14

research field:分子生物学蛋白质生物化学血液学遗传学

Abstract

Haemophilia A (HA) is a rare congenital, recessive X-linked bleeding disorders caused by the lack or deficiency of clotting factor VIII (FVIII). Missense variants, which can alter protein structure, conformation and immunogenicity, are found in nearly all individuals with mild or moderate hemophilia A but in fewer than 20% of those with the severe form. Here, we identified a 26-year-old man with a hemizygous F8 mutation (NM_000132.4(F8):c.5399 G > A (p. Arg 1800 His)) through direct sequencing of all exons of the F8 gene, which is established to cause a lack of FVIII:c (%) in circulating blood and leads to moderate HA. In addition, we also provide evidence for the reduced active FVIII (FVIII:c (%)) caused by p. Arg 1800 His mutation. In detail, we show that p. Arg 1800 His mutation may activate the unfolded protein response through IRE1a-XBP1 pathway and reduce stability of FVIII. Results from co-immunoprecipitation assays showed that p. Arg 1800 His mutation decreases the interaction between FVIII and PDIA5. Furthermore, unbiased molecular dynamics simulations highlight the importance of Arg1800 in the interactions FVIII and von Willebrand factor. These findings demonstrate the crucial role of Arg1800 in the correct biogenesis of FVIII and shed light on molecular mechanisms through which missense mutations in FVIII contribute to the development of moderate hemophilia A.

本文使用的Yeasen产品

购物车
客服
转染试用